Cure8 research brief
This preclinical study suggests cyanidin-3-O-glucoside (a dietary anthocyanin) can reduce inflammation and modify gut microbes and metabolites in an experimental colitis model by inhibiting NF-κB signaling. It points to potential new biological pathways that could be relevant to IBD research.
Researchers in IBD, microbiome scientists, clinicians following experimental therapeutics, and informed patients interested in preclinical dietary-compound research.
This study reports that cyanidin-3-O-glucoside (C3G), a natural anthocyanin, reduced inflammation and tissue damage in a DSS-induced mouse model of colitis and inhibited NF-κB signaling in cells and mouse tissue.
The authors also measured shifts in gut microbiota by 16S sequencing and performed metabolomics, identifying 1-deoxynojirimycin (1-DNJ) as associated with C3G treatment.
C3G treatment was linked to lower pro-inflammatory cytokines (IL‑1β, IL‑6, TNF‑α) and higher IL‑10 in the experimental model, and to markers consistent with increased anti-inflammatory macrophage polarization.
Microbiome composition changed with fewer taxa the authors considered pathogenic and enrichment of microbes viewed as beneficial; metabolomic profiling highlighted 1‑DNJ among altered metabolites. This is an experimental preclinical study using a chemical colitis model in mice and in vitro macrophage experiments.
The findings describe biological effects and associations that support further mechanistic work but do not establish safety or efficacy in humans.
Findings come from a DSS-induced mouse model and in vitro macrophage assays; metabolomic and microbiome changes are associative. This is not evidence of safety or effectiveness in humans.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Special Fund Project for Basic Research of Zhenjiang - JC2024035; Innovation Special Fund of Danyang - SSF202410; Zhenjiang Science and Technology Plan - SH2024047
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...
Some people with Crohn’s have ongoing GI symptoms despite little visible inflammation. This study suggests the gut microbiome—particularly sulfur-producing bacteria—may be a reason, and diet could be a potential target...
